Note 21 - Subsequent Events

The Company evaluated subsequent events for potential recognition or disclosure in the consolidated financial statements through September 22, 2026, the date the consolidated financial statements were issued and included in this Annual Report on Form 10-K. Other than the matters described below and elsewhere in this Annual Report, the Company concluded that there were no subsequent events requiring recognition or disclosure in the consolidated financial statements.

Cotempla Authorized Generic

Pursuant to the Company's license agreement with Teva, Teva's right to manufacture and market an authorized generic version of Cotempla commenced on July 1, 2026 (see Note 19 - License Agreements for further detail). The Company is unable to estimate the financial effect on future net revenue at this time.

Eclipse Incremental Advance

In July 2026, the Company repaid in full the remaining $0.1 million outstanding balance of the Eclipse Incremental Advance under the Eclipse Revolving Loan (see Note 10 - Revolving Credit Facility for further detail).

No other events have occurred subsequent to June 30, 2026, and through the issuance date of these consolidated financial statements that would require recognition or disclosure in the consolidated financial statements.